Edition:
India

Celldex Therapeutics Inc (CLDX.OQ)

CLDX.OQ on NASDAQ Stock Exchange Capital Market

2.51USD
1:30am IST
Change (% chg)

$0.00 (+0.00%)
Prev Close
$2.51
Open
$2.55
Day's High
$2.55
Day's Low
$2.47
Volume
21,149
Avg. Vol
42,764
52-wk High
$11.55
52-wk Low
$2.02

Latest Key Developments (Source: Significant Developments)

Celldex Therapeutics Reports Q4 Loss Per Share $0.03
Thursday, 8 Mar 2018 

March 7 (Reuters) - Celldex Therapeutics Inc ::CELLDEX PROVIDES CORPORATE UPDATE AND REPORTS FULL YEAR 2017 RESULTS.Q4 LOSS PER SHARE $0.03.CELLDEX THERAPEUTICS - ANTICIPATE TOPLINE PRIMARY ENDPOINT DATA FROM METRIC STUDY OF GLEMBATUMUMAB VEDOTIN WILL BE AVAILABLE IN Q2 OF 2018.Q4 REVENUE $3.5 MILLION VERSUS $1.9 MILLION.  Full Article

Celldex Therapeutics Q3 loss per share $0.20
Tuesday, 7 Nov 2017 

Nov 7 (Reuters) - Celldex Therapeutics Inc :Q3 revenue $3.9 million versus $2.2 million .Celldex reports third quarter 2017 results.Q3 revenue view $1.1 million -- Thomson Reuters I/B/E/S.Q3 loss per share $0.20.Q3 earnings per share view $-0.27 -- Thomson Reuters I/B/E/S.Celldex Therapeutics Inc - ‍ projects that topline primary endpoint data should be available in Q2 of 2018 for metric​.Celldex therapeutics inc - ‍by year-end, celldex plans to initiate an open-label phase 2 study of CDX-3379 given in combination with erbitux​.  Full Article